Home > Boards > US Listed > Medical - Drugs > Sol Gel Technologies Ltd (SLGL)

Since i am staying at home, i have

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 120
Posts 25,359
Boards Moderated 8
Alias Born 02/07/04
160x600 placeholder
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/22/2021 1:25:07 PM
Raymond James: These 3 Stocks Are Poised to Surge by at Least 50% TipRanks - 3/10/2021 10:29:53 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/9/2021 1:07:46 PM
Sol-Gel Technologies reports FY 2020 results Seeking Alpha - 3/4/2021 7:55:57 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/4/2021 7:43:55 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/4/2021 7:38:05 AM
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update GlobeNewswire Inc. - 3/4/2021 7:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/1/2021 6:32:50 AM
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global ... GlobeNewswire Inc. - 2/24/2021 7:05:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/11/2021 11:13:48 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/5/2021 6:06:42 AM
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Co... GlobeNewswire Inc. - 1/11/2021 7:05:00 AM
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulga... GlobeNewswire Inc. - 12/7/2020 7:05:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 9:12:06 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/12/2020 9:08:36 AM
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update GlobeNewswire Inc. - 11/12/2020 7:05:00 AM
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020 GlobeNewswire Inc. - 11/9/2020 7:05:00 AM
Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020 GlobeNewswire Inc. - 11/4/2020 4:05:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/14/2020 9:14:10 AM
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammat... GlobeNewswire Inc. - 9/10/2020 4:01:10 PM
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September GlobeNewswire Inc. - 9/8/2020 7:05:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/3/2020 8:41:29 AM
Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii® GlobeNewswire Inc. - 9/3/2020 7:05:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 10:40:18 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/6/2020 10:37:55 AM
midastouch017   Sunday, 04/19/20 03:53:51 AM
Re: None
Post # of 36 
Since i am staying at home, i have lots
of time doing research.

One of my largest holdings is GMDA

Gamida Cell Announces Completion of Patient Enrollment in Ongoing Phase 3 Clinical Study of Omidubicel
January 2, 2020 at 8:01 AM EST
PDF Version
– Topline data expected in first half of 2020 –

BOSTON--(BUSINESS WIRE)--Jan. 2, 2020-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the company completed patient enrollment in its Phase 3 study of the company’s lead clinical program, omidubicel, an investigational advanced cell therapy being evaluated as a potential life-saving treatment option for patients with high-risk hematologic malignancies who are in need of a bone marrow transplant. Topline data from the study are expected in the first half of 2020.

“Completing patient recruitment for the Phase 3 study of omidubicel is a very significant milestone for our company,” stated Julian Adams, Ph.D., chief executive officer of Gamida Cell. “Positive data would enable us to file our first biologics license application in the second half of 2020 and would represent an important step toward becoming a fully integrated company that can bring breakthrough medicines to patients.”

It is estimated that more than 40 percent of eligible patients in the U.S. do not receive a bone marrow transplant for various reasons, including inability to find a matched donor, despite its curative potential.1 Even for patients who do receive a transplant, the procedure is not always effective and can lead to serious complications that dramatically affect quality of life.2 Omidubicel is intended to address the current limitations of bone marrow transplant by providing a therapeutic dose of stem cells while preserving the cells’ functional therapeutic characteristics.

“For many patients with high-risk hematologic malignancies who are in remission, their only hope of remaining cancer-free is to undergo a bone marrow transplant. While the scientific community has made strides in improving bone marrow transplant, there is still a significant need to make this potentially curative treatment option available to more patients,” said Ronit Simantov, M.D., chief medical officer of Gamida Cell. “We truly appreciate the participation of patients and the support we have received from investigators who believe this clinical trial is critical for moving the field forward.”

The international, multi-center, randomized Phase 3 study (NCT02730299) is designed to evaluate the safety and efficacy of omidubicel compared to standard umbilical cord blood in patients with high-risk hematologic malignancies who need a bone marrow transplant and do not have an available matched donor. The primary endpoint is time to neutrophil engraftment. The study includes approximately 120 patients aged 12-65 with acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome or lymphoma. The study is taking place at over 50 clinical centers in the U.S., Latin America, Europe and Asia.

About Omidubicel
Omidubicel (formerly known as NiCord®), the company’s lead clinical program, is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has also received Orphan Drug Designation in the U.S. and EU. In a Phase 1/2 clinical study, omidubicel demonstrated rapid and durable time to engraftment and was generally well tolerated.3 A Phase 3 study evaluating omidubicel in patients with leukemia and lymphoma is ongoing in the U.S., Latin America, Europe and Asia.4 Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia.5 The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn®, which is the same investigational development candidate as omidubicel. For more information on clinical trials of omidubicel, please visit www.clinicaltrials.gov.

Omidubicel is an investigational therapy, and its safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit
https://www.gamida-cell.com/

Mind you, i am not recommending to follow my footsteps. i
have made many investing mistakes, made a fortune and
encountered HUGE losses as well.

Finally results for both BVXV and GMDA are not too far away!





Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences